Home / Market News / $GLUE
benzinga Corporate Catalyst Impact 55/100 ● neutral

HC Wainwright & Co. Reiterates Buy on Monte Rosa Therapeutics, Maintains $25 Price Target

Oct 5, 2026, 11:46 AM UTC · Primary ticker $GLUE

HC Wainwright & Co. analyst Mitchell S. Kapoor has reiterated a 'Buy' rating and maintained a $25 price target for Monte Rosa Therapeutics. This filing indicates continued analyst confidence in the company's prospects, which could provide some positive sentiment for investors.

This 8-K filing discloses that HC Wainwright & Co. analyst Mitchell S. Kapoor has reiterated a 'Buy' rating on Monte Rosa Therapeutics (GLUE) and maintained a $25 price target. This action signals continued analyst confidence in the company's valuation and future performance. For traders, this provides a positive signal, potentially reinforcing existing bullish positions or attracting new investors. While not a new catalyst, the reiteration of a positive stance from a research firm can help maintain positive momentum or provide a floor for the stock in the short term. The long-term implications depend on the company's actual performance relative to the analyst's expectations. A key opportunity for traders is to consider this analyst endorsement as part of their broader due diligence on GLUE.

$GLUE positive Analyst reiterates Buy rating and price target
Source: benzinga
Join the waitlist for full signal validation →

Not financial advice. AI-generated analysis for informational purposes only.